{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:44:24Z","timestamp":1793598264387,"version":"4.5.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"Supplement_K","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Watermeadow Medical"},{"name":"Ashfield Company"},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with comorbidities are often excluded from clinical trials, limiting the evidence base for pulmonary arterial hypertension (PAH)-specific therapies. This review aims to discuss the effect of comorbidities on the diagnosis and management of PAH. The comorbidities discussed in this review (systemic hypertension, obesity, sleep apnoea, clinical depression, obstructive airway disease, thyroid disease, diabetes, and ischaemic cardiovascular event) were chosen based on their prevalence in patients with idiopathic PAH in the REVEAL registry (Registry to EValuate Early and Long-term PAH disease management). Comorbidities can mask the symptoms of PAH, leading to delays in diagnosis and also difficulty evaluating disease progression and treatment effects. Due to the multifactorial pathophysiology of pulmonary hypertension (PH), the presence of comorbidities can lead to difficulties in distinguishing between Group 1 PH (PAH) and the other group classifications of PH. Many comorbidities contribute to the progression of PAH through increased pulmonary artery pressures and cardiac output, therefore treatment of the comorbidity may also reduce the severity of PAH. Similarly, the development of one comorbidity can be a risk factor for the development of other comorbidities. The management of comorbidities requires consideration of drug interactions, polypharmacy, adherence and evidence-based strategies. A multidisciplinary team should be involved in the management of patients with PAH and comorbidities, with appropriate referral to supportive services when necessary. The treatment goals and expectations of patients must be managed in the context of comorbidities.<\/jats:p>","DOI":"10.1093\/eurheartj\/suz205","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T09:07:26Z","timestamp":1576573646000},"page":"K21-K28","source":"Crossref","is-referenced-by-count":71,"title":["The burden of comorbidities in pulmonary arterial hypertension"],"prefix":"10.1093","volume":"21","author":[{"given":"Irene M","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Palazzini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Zamboni, 33 - 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2019121704072321000_suz205-B1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0021-9681(70)90054-8","article-title":"The pre-therapeutic classification of co-morbidity in chronic disease","volume":"23","author":"Feinstein","year":"1970","journal-title":"J Chronic Dis"},{"key":"2019121704072321000_suz205-B2","doi-asserted-by":"crossref","first-page":"e0154387.","DOI":"10.1371\/journal.pone.0154387","article-title":"Genetic factors are not the major causes of chronic diseases","volume":"11","author":"Rappaport","year":"2016","journal-title":"PLoS One"},{"key":"2019121704072321000_suz205-B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"2019121704072321000_suz205-B4","doi-asserted-by":"crossref","first-page":"1702310.","DOI":"10.1183\/13993003.02310-2017","article-title":"Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension","volume":"51","author":"Hjalmarsson","year":"2018","journal-title":"Eur Respir J"},{"key":"2019121704072321000_suz205-B5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2019121704072321000_suz205-B6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.11-3241","article-title":"Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis","volume":"144","author":"Poms","year":"2013","journal-title":"Chest"},{"key":"2019121704072321000_suz205-B7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"2019121704072321000_suz205-B8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"2019121704072321000_suz205-B9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1183\/16000617.0079-2016","article-title":"Pregnancy in pulmonary arterial hypertension","volume":"25","author":"Olsson","year":"2016","journal-title":"Eur Respir J"},{"key":"2019121704072321000_suz205-B10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"2019121704072321000_suz205-B11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/thx.2010.147272","article-title":"Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension","volume":"66","author":"Soon","year":"2011","journal-title":"Thorax"},{"key":"2019121704072321000_suz205-B12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/690018","article-title":"Kidney dysfunction in patients with pulmonary arterial hypertension","volume":"7","author":"Nickel","year":"2017","journal-title":"Pulm Circ"},{"key":"2019121704072321000_suz205-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cld.401","article-title":"Portopulmonary hypertension: diagnosis, clinical features, and medical therapy","volume":"4","author":"Bartolome","year":"2014","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2019121704072321000_suz205-B14","doi-asserted-by":"crossref","first-page":"328435.","DOI":"10.1155\/2015\/328435","article-title":"Lupus-associated pulmonary arterial hypertension: variable course and importance of prompt recognition","volume":"2015","author":"Mensah","year":"2015","journal-title":"Case Rep Med"},{"key":"2019121704072321000_suz205-B15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1513\/AnnalsATS.201609-674OC","article-title":"Characterization of prostacyclin-associated leg pain in patients with pulmonary arterial hypertension","volume":"14","author":"Pagani-Est\u00e9vez","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2019121704072321000_suz205-B16","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.rmed.2007.06.014","article-title":"Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension","volume":"101","author":"Bauer","year":"2007","journal-title":"Respir Med"},{"key":"2019121704072321000_suz205-B17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.numecd.2014.10.005","article-title":"Pulmonary arterial hypertension-related myopathy: an overview of current data and future perspectives","volume":"25","author":"Marra","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2019121704072321000_suz205-B18","doi-asserted-by":"crossref","first-page":"2481659.","DOI":"10.1155\/2016\/2481659","article-title":"The role of hyperglycemia and insulin resistance in the development and progression of pulmonary arterial hypertension","volume":"2016","author":"Grinnan","year":"2016","journal-title":"J Diabetes Res"},{"key":"2019121704072321000_suz205-B19","doi-asserted-by":"crossref","first-page":"e003973.","DOI":"10.1161\/CIRCOUTCOMES.117.003973","article-title":"Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada","volume":"11","author":"Wijeratne","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2019121704072321000_suz205-B20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/16000617.0063-2015","article-title":"Pulmonary arterial hypertension: the burden of disease and impact on quality of life","volume":"24","author":"Delcroix","year":"2015","journal-title":"Eur Respir Rev"},{"key":"2019121704072321000_suz205-B21","doi-asserted-by":"crossref","first-page":"e0151425.","DOI":"10.1371\/journal.pone.0151425","article-title":"Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Kreuter","year":"2016","journal-title":"PLoS One"},{"key":"2019121704072321000_suz205-B22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/fampra\/cmp020","article-title":"Multimorbidity in primary care: developing the research agenda","volume":"26","author":"Mercer","year":"2009","journal-title":"Fam Pract"},{"key":"2019121704072321000_suz205-B23","doi-asserted-by":"crossref","first-page":"ehz746.0032","DOI":"10.1093\/eurheartj\/ehz746.0032","article-title":"Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities","volume":"40(Suppl.1)","author":"Rosenkranz","year":"2019","journal-title":"Eur Heart J"},{"key":"2019121704072321000_suz205-B24","first-page":"A2196","article-title":"A comparison of characteristics and outcomes of patients with atypical and classical pulmonary arterial hypertension from the AMBITION trial","volume":"191","author":"Mclaughlin","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2019121704072321000_suz205-B25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum","volume":"68","author":"Opitz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2019121704072321000_suz205-B26","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"G\u00fcnther","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2019121704072321000_suz205-B27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1183\/09059180.00007814","article-title":"The changing landscape of pulmonary arterial hypertension and implications for patient care","volume":"23","author":"Hoeper","year":"2014","journal-title":"Eur Respir Rev"},{"key":"2019121704072321000_suz205-B28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1378\/chest.10-1166","article-title":"Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry","volume":"140","author":"Brown","year":"2011","journal-title":"Chest"},{"key":"2019121704072321000_suz205-B29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2045-8932.109919","article-title":"Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study","volume":"3","author":"Strange","year":"2013","journal-title":"Pulm Circ"},{"key":"2019121704072321000_suz205-B30","doi-asserted-by":"crossref","first-page":"K9","DOI":"10.1093\/eurheartj\/suz204","article-title":"Screening strategies for pulmonary arterial hypertension","volume":"21","author":"Kiely","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"2019121704072321000_suz205-B31","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1093\/eurheartj\/suz206","article-title":"Management of pulmonary arterial hypertension in patients aged over 65 years","volume":"21","author":"Sitbon","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"2019121704072321000_suz205-B32","first-page":"w14462","article-title":"Rehabilitation in patients with pulmonary arterial hypertension","volume":"147","author":"Keusch","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"2019121704072321000_suz205-B33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.chest.2016.10.043","article-title":"Pulmonary hypertension care center network: improving care and outcomes in pulmonary hypertension","volume":"151","author":"Sahay","year":"2017","journal-title":"Chest"},{"key":"2019121704072321000_suz205-B34","first-page":"A18122","article-title":"Abstract 18122: cardiac rehabilitation in subjects with peripheral arterial disease: a higher risk patient population who benefit from attendance","volume":"134(Suppl_1)","author":"Martin","year":"2016","journal-title":"Circulation"},{"key":"2019121704072321000_suz205-B35","doi-asserted-by":"crossref","first-page":"e000163.","DOI":"10.1136\/openhrt-2014-000163","article-title":"Exercise-based rehabilitation for heart failure: systematic review and meta-analysis","volume":"2","author":"Sagar","year":"2015","journal-title":"Open Heart"},{"key":"2019121704072321000_suz205-B36","first-page":"481","article-title":"Cardiac rehabilitation following myocardial infarction","volume":"15","author":"Piotrowicz","year":"2008","journal-title":"Cardiol J"},{"key":"2019121704072321000_suz205-B37","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/clc.23001","article-title":"The role and outcome of cardiac rehabilitation program in patients with atrial fibrillation","volume":"41","author":"Younis","year":"2018","journal-title":"Clin Cardiol"},{"key":"2019121704072321000_suz205-B38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijcard.2018.08.082","article-title":"Targeted therapy of pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018","volume":"272","author":"Hoeper","year":"2018","journal-title":"Int J Cardiol"},{"key":"2019121704072321000_suz205-B39","first-page":"160","article-title":"Treatment of systemic hypertension","volume":"2","author":"Aronow","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"2019121704072321000_suz205-B40","first-page":"e21","article-title":"Heart disease and stroke statistics\u20132009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"2019121704072321000_suz205-B41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5539\/gjhs.v7n4p307","article-title":"Recent strategies in treatment of pulmonary arterial hypertension, a review","volume":"7","author":"Fallah","year":"2015","journal-title":"Glob J Health Sci"},{"key":"2019121704072321000_suz205-B42","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term pah disease management (REVEAL)","volume":"132","author":"Preston","year":"2015","journal-title":"Circulation"},{"key":"2019121704072321000_suz205-B43","doi-asserted-by":"crossref","first-page":"S120.","DOI":"10.1016\/j.healun.2016.01.329","article-title":"Anticoagulant therapy is not associated with long term outcome in patients with pulmonary arterial hypertension (PAH): insights from the GRIPHON Study","volume":"35","author":"Tapson","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2019121704072321000_suz205-B44","first-page":"48","article-title":"Anticoagulation in pulmonary arterial hypertension: contemporary data from COMPERA registry","volume":"2014","author":"Said","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"key":"2019121704072321000_suz205-B45","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.chest.2018.05.006","article-title":"Association between BMI and obesity with survival in pulmonary arterial hypertension","volume":"154","author":"Weatherald","year":"2018","journal-title":"Chest"},{"key":"2019121704072321000_suz205-B46","first-page":"PA3521","article-title":"Is there an obesity paradox in pulmonary arterial hypertension?","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"key":"2019121704072321000_suz205-B47","doi-asserted-by":"crossref","first-page":"912.","DOI":"10.3390\/ijms20040912","article-title":"Pulmonary hypertension and obesity: focus on adiponectin","volume":"20","author":"Perrotta","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2019121704072321000_suz205-B48","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.soard.2018.07.015","article-title":"Bariatric surgery in patients with pulmonary hypertension","volume":"14","author":"Hanipah","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"2019121704072321000_suz205-B49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00464-015-4251-5","article-title":"Improvement in severe pulmonary hypertension in obese patients after laparoscopic gastric bypass or sleeve gastrectomy","volume":"30","author":"Sheu","year":"2016","journal-title":"Surg Endosc"},{"key":"2019121704072321000_suz205-B50","doi-asserted-by":"crossref","first-page":"505274.","DOI":"10.1155\/2012\/505274","article-title":"Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms","volume":"2012","author":"Friedman","year":"2012","journal-title":"J Obes"},{"key":"2019121704072321000_suz205-B51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pcad.2008.06.001","article-title":"Obstructive sleep apnea and pulmonary hypertension","volume":"51","author":"Sajkov","year":"2009","journal-title":"Prog Cardiovasc Dis"},{"key":"2019121704072321000_suz205-B52","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/thorax.55.11.934","article-title":"Pulmonary arterial hypertension in patients with sleep apnoea syndrome","volume":"55","author":"Bady","year":"2000","journal-title":"Thorax"},{"key":"2019121704072321000_suz205-B53","first-page":"240","article-title":"Depression in pulmonary arterial hypertension and interstitial lung diseases","volume":"6","author":"Verma","year":"2014","journal-title":"N Am J Med Sci"},{"key":"2019121704072321000_suz205-B54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.psy.0000145593.37594.39","article-title":"Anxiety and depression in patients with pulmonary hypertension","volume":"66","author":"Lowe","year":"2004","journal-title":"Psychosom Med"},{"key":"2019121704072321000_suz205-B55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/0970-2113.173072","article-title":"Depression in pulmonary arterial hypertension: an undertreated comorbidity","volume":"33","author":"Verma","year":"2016","journal-title":"Lung India"},{"key":"2019121704072321000_suz205-B56","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1378\/chest.12-2081","article-title":"Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension","volume":"144","author":"Sadoughi","year":"2013","journal-title":"Chest"},{"key":"2019121704072321000_suz205-B57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hrtlng.2004.06.010","article-title":"Living with pulmonary artery hypertension: patients' experiences","volume":"34","author":"Flattery","year":"2005","journal-title":"Heart Lung"},{"key":"2019121704072321000_suz205-B58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1590\/S1806-37132009000200012","article-title":"Pulmonary arterial hypertension and thyroid disease","volume":"35","author":"Silva","year":"2009","journal-title":"J Bras Pneumol"},{"key":"2019121704072321000_suz205-B59","first-page":"174","article-title":"Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism","volume":"20","author":"Tudoran","year":"2018","journal-title":"Anatol J Cardiol"},{"key":"2019121704072321000_suz205-B60","first-page":"93","article-title":"Thyroid gland and pulmonary hypertension. What's the link?","volume":"55","author":"Marvisi","year":"2013","journal-title":"Panminerva Med"},{"key":"2019121704072321000_suz205-B61","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1210\/jc.2012-1109","article-title":"Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination","volume":"97","author":"Trapp","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2019121704072321000_suz205-B62","doi-asserted-by":"crossref","first-page":"702.e7","DOI":"10.1016\/j.amjmed.2017.12.046","article-title":"Diabetes mellitus associates with increased right ventricular afterload and remodeling in pulmonary arterial hypertension","volume":"131","author":"Whitaker","year":"2018","journal-title":"Am J Med"},{"key":"2019121704072321000_suz205-B63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/675994","article-title":"Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension","volume":"4","author":"Benson","year":"2014","journal-title":"Pulm Circ"},{"key":"2019121704072321000_suz205-B64","doi-asserted-by":"crossref","first-page":"e009235.","DOI":"10.1136\/bmjopen-2015-009235","article-title":"Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review","volume":"5","author":"Cooper","year":"2015","journal-title":"BMJ Open"},{"key":"2019121704072321000_suz205-B65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2019121704072321000_suz205-B66","first-page":"A138","article-title":"DI-058 Risk of drug\u2013drug interactions in a pulmonary arterial hypertension population","volume":"24(Suppl 1)","author":"Su\u00e1rez","year":"2017","journal-title":"Eur J Hosp Pharm"},{"key":"2019121704072321000_suz205-B67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","volume":"60","author":"Paul","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"2019121704072321000_suz205-B68","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"2019121704072321000_suz205-B69","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"2019121704072321000_suz205-B70","doi-asserted-by":"crossref","first-page":"42m","DOI":"10.1016\/j.amjcard.2005.07.011","article-title":"Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions","volume":"96","author":"Kloner","year":"2005","journal-title":"Am J Cardiol"},{"key":"2019121704072321000_suz205-B71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.15420\/usc.2009.6.2.101","article-title":"Drug interactions in pulmonary arterial hypertension and their implications","volume":"6","author":"Ghofrani","year":"2009","journal-title":"US Cardiol"},{"key":"2019121704072321000_suz205-B72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","article-title":"Pulmonary arterial hypertension: combination therapy in practice","volume":"18","author":"Burks","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2019121704072321000_suz205-B73","first-page":"2045893217743616","article-title":"Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies","volume":"8","author":"Grady","year":"2017","journal-title":"Pulm Circ"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_K\/K21\/31538814\/suz205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_K\/K21\/31538814\/suz205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T17:37:08Z","timestamp":1665250628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_K\/K21\/5678702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":73,"journal-issue":{"issue":"Supplement_K","published-online":{"date-parts":[[2019,12,17]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suz205","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}